trending Market Intelligence /marketintelligence/en/news-insights/trending/2NI0F-mFPZ9Tg_wVhH8DLg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Boston Scientific enters $4.75B worth of credit, loan agreements

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Boston Scientific enters $4.75B worth of credit, loan agreements

Boston Scientific Corp. said it entered a new $2.75 billion revolving credit agreement as well as a $2 billion term loan agreement to finance the BTG PLC acquisition.

The Marlborough, Mass.-based medical device maker, which also amended a previous $1 billion credit agreement, agreed to buy London-based BTG in November for £3.3 billion.

Bank of America is acting as the syndication agent and Wells Fargo Bank as administrative agent for the $2.75 billion credit agreement, with Barclays Bank PLC acting as administrative agent for the $2 billion loan.

The new $2.75 billion credit facility will mature on Dec. 19, 2023, and the final tranche from the $2 billion loan will mature three years after the closing of the BTG acquisition.

Boston Scientific also terminated two of its previous revolving credit agreements dated Aug. 4, 2017, and Feb. 7, 2017.